Other immunological parameters will be measured and include: 
a. cytokine mRNA expression 
b. cytotoxicity against various targets 
c. phenotype 
Clinical parameters will be measured and include: 
a. objective tumor response 
b. clinical toxicity 
A summary of biological response modifier administration is shown below: 
Weeks: 1-4, 7-10, 13-16, 19-22. Representative Week of Therapy. 
Study Day 1 2 3 4 5 6 7 Dose/Route 
rIL-2 X X X X 2 x 10 6 U/m 2 /day 
IFNaA* X X 6 x 10 6 U/m 2 /day 
IM or SC 
TIL or PBL** X 
10 9 -10" cells 
IV 
No Treatment During Weeks: 5-6, 11-12, 17-18 
X = Drug administered 
= Continuous intravenous infusion 
= Intramuscular injection 
= Subcutaneous injection 
= Intravenous infusion 
= IFNaA administered to renal cancer pts only 
= Administered on day one of week one 
CIV 
IM 
SC 
IV 
* 
** 
5.2 Number of patients 
Up to forty (40) evaluable patients will be treated - 20 melanoma and 20 renal. 
[522] 
Recombinant DNA Research, Volume 15 
